FDA guides on minimal residual disease endpoint in hematologic cancer trials

FDA Commissioner Scott Gottlieb highlighted minimal residual disease (MRD)'s potential as a surrogate endpoint in clinical trials when he unveiled FDA's draft guidance on using MRD in hematologic malignancy drug development in a statement Monday.

As early as 2012, FDA co-sponsored public workshops

Read the full 421 word article

How to gain access

Continue reading with a
two-week free trial.